Migraine – A common brain neurological condition


Migraine – A common brain neurological condition

The medical term migraine has its roots in the Greek language, and means “half of the head”. A migraine can cause severe, often throbbing pain, usually on one side of the head, while 50% of people experience pain on both sides. It is often accompanied by nausea, vomiting, dizziness, extreme sensitivity to light, noise and odors, lack of appetite, intestinal dysfunction and worsening of symptoms with activity.

Although a migraine episode can last from 4 to 72 hours, people with chronic migraines have at least 8 migraine episodes per month and at least 15 days a month headache of any kind.

Finding the primary cause(s) of migraine is imperative in order to treat it.

In some cases there may be a genetic predisposition, but the expression of migraine is directly related to the general health status of an individual.


The warning signs

Warning signs which are known as an “aura” can occur before or with a headache. These may include flashes of light, blind spots or tingling on one side of the face or on the arm or leg.

Migraines can imitate the symptoms of a stroke and be the result of a stroke.

The more complex manifestations of migraine may not include headache as a prominent symptom. These are called “Late Life Migrainous Accompaniments”, but despite their name they can also occur in those who are 40 years old.

Dizziness, slurred speech, tinnitus, double vision, trembling gait and loss of consciousness may be associated with migraine and brain aura.


The statistics

Migraines are the most common neurological disorder.

4.4% of patients visit general doctors, 5% are hospitalized and 20% are still a topic of discussion and concern of many neurologists.

20% of women and 10% of men experience migraine headaches during their lifetime.

Patients with chronic migraines are at risk for drug abuse syndrome, to the extent that most people use painkillers for almost ten days a month.


The Causal Factors

A combination of genetic and environmental factors seems to play a role in migraine. Various chemical imbalances in the brain – including the hormone serotonin, which helps regulate pain in the nervous system – can also be involved. Serotonin levels fall during the onset of a migraine. This can stimulate the trigeminal nerve to release substances called neuropeptides, which are carried to the outer area of the brain. The result is pain.

Other neurotransmitters have been found to play a role in pain, including the calcitonin gene-related peptide (CGRP).

environmental factors such as sensitivities to food, chemicals, alcohol, stress, changes in sleep, as well as physical factors such as changes in weather or barometric pressure are  Also important

Finally, great importance is given to the role of the intestine with emphasis on its microbiome as well as the different combination of bacteria that can, for example, make people more sensitive to certain foods. This activates the immune system and it changes the permeability of the intestine (“leaking intestine”).


Menopausal hormones

Migraines are often associated with the menstrual cycle with premenstrual migraines being more common. These can occur either at the beginning of the period or during ovulation.

The cause is the dominance of estrogen (more estrogen than progesterone), which can aggravate headaches.

They can also occur during menstruation when inflammatory prostaglandin (PG) levels are high inside the uterus.


The fluctuation of blood glucose and insulin

Insulin is the hormone that increases during the consumption of carbohydrates and leads the glucose to the cells with the aim of producing energy in cases of its rapid increase and its rapid decrease (hypoglycemia). After consuming  processed carbohydrates and sugar, insulin can lead to the development of migraine.


Stress hormones

Not surprisingly, stress is a major cause of migraines. Constant stress can increase the levels of catecholamine, dopamine, adrenaline, noradrenaline and cortisol ( the adrenal hormone) in the bloodstream. These increases can cause migraines.


The therapeutic approach

Conventional treatment prescribes the immediate use of drugs after the onset of symptoms. Unfortunately, all of these drugs can have side effects and do not promise a definitive cure.

Based on the above etiological factors, it would be appropriate to mention some of the most useful therapeutic approaches to the prognosis and treatment of migraine.

The evaluation and balance of hormones is always considered necessary in combination with a proper lifestyle that includes proper nutrition, supplements of vitamins and minerals, use of herbs and natural hormones.

Given that proper treatment presupposes the correct approach and radical endoscopy of both the causes and the overall condition of the patient, the prognosis sets the cubit high enough and the total elimination of the disease and the symptoms is no longer impossible.



Dr. Nikoleta Koini, M.D.

Doctor of Functional, Preventive, Anti-ageing and Restorative Medicine.
Diplomate and Board Certified in Anti-aging, Preventive, Functional and Regenerative Medicine from A4M (American Academy in Antiaging Medicine).



  • Gilmore B, Michael M (February 2011). “Treatment of acute migraine headache”. American Family Physician. 83 (3): 271–80. PMID 21302868.
  • Amin, Faisal Mohammad; Aristeidou, Stavroula; Baraldi, Carlo; Czapinska-Ciepiela, Ewa K.; Ariadni, Daponte D.; Di Lenola, Davide; Fenech, Cherilyn; Kampouris, Konstantinos; Karagiorgis, Giorgos; Braschinsky, Mark; Linde, Mattias (2018-09-10). “The association between migraine and physical exercise”. The Journal of Headache and Pain. 19 (1): 83. doi:10.1186/s10194-018-0902-y. ISSN 1129-2369. PMC 6134860. PMID 30203180.
  • “NINDS Migraine Information Page”. National Institute of Neurological Disorders and Stroke. November 3, 2015. Archived from the original on 16 February 2016. Retrieved 15 February 2016.
  • Diener HC, Charles A, Goadsby PJ, Holle D (October 2015). “New therapeutic approaches for the prevention and treatment of migraine”. The Lancet. Neurology. 14 (10): 1010–22. doi:10.1016/s1474-4422(15)00198-2. PMID 26376968. S2CID 26523013.
  • Gobel, Hartmut. “1. Migraine”. ICHD-3 The International Classification of Headache Disorders 3rd edition. Retrieved 2020-10-22.
  • May A, Burstein R (November 2019). “Hypothalamic regulation of headache and migraine”. Cephalalgia. 39 (13): 1710–1719. doi:10.1177/0333102419867280. PMC 7164212. PMID 31466456.
  • Ashina, Messoud (5 November 2020). “Migraine”. New England Journal of Medicine. 383 (19): 1866–1876. doi:10.1056/NEJMra1915327. PMID 33211930.
  • Qubty W, Patniyot I (June 2020). “Migraine Pathophysiology”. Pediatric Neurology. 107: 1–6. doi:10.1016/j.pediatrneurol.2019.12.014. PMID 32192818.
  • Robbins MS, Lipton RB (April 2010). “The epidemiology of primary headache disorders”. Seminars in Neurology. 30 (2): 107–19. doi:10.1055/s-0030-1249220. PMID 20352581.
  • Schürks M (January 2012). “Genetics of migraine in the age of genome-wide association studies”. The Journal of Headache and Pain. 13 (1): 1–9. doi:10.1007/s10194-011-0399-0. PMC 3253157. PMID 22072275.
  • Pavlovic JM, Buse DC, Sollars CM, Haut S, Lipton RB (2014). “Trigger factors and premonitory features of migraine attacks: summary of studies”. Headache. 54 (10): 1670–9. doi:10.1111/head.12468. PMID 25399858. S2CID 25016889.
  • Chai NC, Peterlin BL, Calhoun AH (June 2014). “Migraine and estrogen”. Current Opinion in Neurology. 27 (3): 315–24. doi:10.1097/WCO.0000000000000091. PMC 4102139. PMID 24792340.
  • Andreou AP, Edvinsson L (December 2019). “Mechanisms of migraine as a chronic evolutive condition”. The Journal of Headache and Pain. 20 (1): 117. doi:10.1186/s10194-019-1066-0. PMC 6929435. PMID 31870279.
  • “What is Migraine?”. Migraine Research Foundation. Archived from the original on 2020-06-04.
  • Chen D, Willis-Parker M, Lundberg GP (October 2019). “Migraine headache: Is it only a neurological disorder? Links between migraine and cardiovascular disorders”. Trends in Cardiovascular Medicine. 30 (7): 424–430. doi:10.1016/j.tcm.2019.10.005. PMID 31679956.
  • Linde K, Allais G, Brinkhaus B, Fei Y, Mehring M, Vertosick EA, et al. (June 2016). “Acupuncture for the prevention of episodic migraine”. The Cochrane Database of Systematic Reviews (6): CD001218. doi:10.1002/14651858.CD001218.pub3. PMC 4977344. PMID 27351677.
  • Millstine D, Chen CY, Bauer B (May 2017). “Complementary and integrative medicine in the management of headache”. BMJ. 357: j1805. doi:10.1136/bmj.j1805. PMID 28512119. S2CID 19155758.
  • “FDA allows marketing of first medical device to prevent migraine headaches”. Mar 11, 2014. Archived from the original on 25 July 2014. Retrieved 25 July 2014.